Southern African Origin of HTLV-1 in Romania.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 12 01 2024
accepted: 03 07 2024
medline: 6 8 2024
pubmed: 6 8 2024
entrez: 6 8 2024
Statut: epublish

Résumé

In Europe, most HTLV-1-infected individuals originate from highly endemic regions such as West Indies, sub-Saharan Africa, and South America. The only genuine endemic region for HTLV-1 in Europe is Romania where ATL series have been reported among Romanian patients. Our objective is to better understand the origin of this endemic focus based on a study of the genetic diversity of HTLV-1 in Romanians. DNA was obtained from PBMCs/buffy coats of 11 unrelated HTLV-1-infected individuals of Romanian origin. They include 9 ATL cases and 2 asymptomatic carriers. LTR sequences were obtained for all specimens. Complete genomic HTLV-1 sequences were obtained using four PCR series on 10 specimens. Phylogenetic trees were generated from multiple alignments using HTLV-1 prototypic sequences and the new generated sequences. Most of the complete LTR sequences (756-bp) showed low nucleotide diversity, ranging from 0% to 0.8% difference, and were closely related (less than 0.8% divergence) to the only previously characterized Romanian strain, RKI2. One strain, ROU7, diverged slightly (1.5% on average) from the others. Phylogenetic analyses both on partial LTR and the complete genome demonstrate that the 11 sequences belong to the HTLV-1a cosmopolitan genotype and 10 of them belong to the previously denominated a-TC Mozambique-Southern Africa A subgroup. In this study, we demonstrated that the HTLV-1 present in Romania most probably originated in Southern Africa. As most Romanian HTLV-1 strains are very closely related, we can assume that HTLV-1 has been introduced into the Romanian population recently. Further studies are ongoing to decipher the routes of arrival and dissemination of these HTLV-1 strains, and to date the emergence of this endemic focus in Central Europe.

Identifiants

pubmed: 39106239
doi: 10.1371/journal.pntd.0012337
pii: PNTD-D-24-00050
doi:

Substances chimiques

DNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0012337

Informations de copyright

Copyright: © 2024 Cassar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Olivier Cassar (O)

Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Unité d'Épidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Paris, France.

Ambroise Marçais (A)

Hôpital Necker-Enfants Malades, Service d'Hématologie, Paris, France.

Olivier Hermine (O)

Hôpital Necker-Enfants Malades, Service d'Hématologie, Paris, France.

Emilie Deruelle (E)

Hôpital Necker-Enfants Malades, Service d'Hématologie, Paris, France.

Giovanni Begliomini (G)

Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Unité d'Épidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Paris, France.

Alexandru Bardas (A)

Fundeni Clinical Institute, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.

Horia Bumbea (H)

Emergency University Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.

Andrei Colita (A)

Coltea Hospital, University of Medicine and Pharmacy Carol Davila, Department of Hematology, Bucharest, Romania.

Daniel Coriu (D)

Fundeni Clinical Institute, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.

Viola Maria Popov (VM)

Colentina Clinical Hospital, Hematology 1 Department, Bucharest, Romania.

Alina Tanase (A)

Fundeni Clinical Institute, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.

Philippe Vicente Afonso (PV)

Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Unité d'Épidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Paris, France.

Antoine Gessain (A)

Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Unité d'Épidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Paris, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH